Patient Area
02
2020
-
03
Corporate Governance
Overview
The company believes that good corporate governance can provide a solid foundation for the group to manage business risks more effectively, increase transparency, promote high standards of accountability, and fully protect the interests of shareholders.
Board of Directors
See the prospectus
Committee
Audit Committee
We established the Audit Committee on June 6, 2020, and its written terms of reference comply with the Listing Rules Section 3.21 and the Corporate Governance Code set out in Appendix 14 of the Listing Rules. The Audit Committee consists of three members, namely two independent non-executive directors, Mr. Wu Zhi Jie (who is the chairman of the Audit Committee), Professor Wang, and one non-executive director, Mr. Tao Ran. Mr. Wu Zhi Jie is an independent non-executive director with appropriate professional qualifications or accounting or related financial management expertise as stipulated in Listing Rules Section 3.10(2). The main responsibilities of the Audit Committee are to provide independent opinions to the Board on the effectiveness of the Group's financial reporting procedures, internal controls, and risk management systems, monitor the audit process, and perform other duties and responsibilities as assigned by the Board.
Remuneration Committee
We established the Remuneration Committee on June 6, 2020, and its written terms of reference comply with the Listing Rules Section 3.25 and the Corporate Governance Code set out in Appendix 14 of the Listing Rules. The Remuneration Committee consists of three members, namely three independent non-executive directors, Mr. Wu Zhi Jie, Mr. Peng Su Jiu, and Mr. Wang Ying Dian (who is the chairman of the Remuneration Committee). The main responsibilities of the Remuneration Committee include (among others) the following matters: (i) to make recommendations to the Board on the remuneration policy and structure for all directors and senior management, and to establish formal and transparent procedures for developing remuneration policies; (ii) to determine specific remuneration packages for directors and senior management; and (iii) to review and approve performance-based remuneration with reference to the corporate objectives and goals as determined by the Board from time to time.
Nomination Committee
We established the Nomination Committee on June 6, 2020, and its written terms of reference comply with the Corporate Governance Code set out in Appendix 14 of the Listing Rules. The Nomination Committee consists of three members, namely two independent non-executive directors, Mr. Peng Su Jiu and Mr. Wang Ying Dian, and one executive director, Mr. Tan (who is the chairman of the Nomination Committee). The main responsibilities of the Nomination Committee are to provide recommendations to the Board on all new appointments of directors and senior management, interview candidates, verify qualifications, and consider related matters.
Shareholders
See the prospectus